| Literature DB >> 21640303 |
Ona Wu1, Lee H Schwamm, A Gregory Sorensen.
Abstract
Stroke is a leading cause of death and adult morbidity worldwide. By defining stroke symptom onset by the time the patient was last known to be well, many patients whose onsets are unwitnessed are automatically ineligible for thrombolytic therapy. Advanced brain imaging may serve as a substitute witness to estimate stroke onset and duration in those patients who do not have a human witness. This article reviews and compares some of these imaging-based approaches to thrombolysis eligibility, which can potentially expand the use of thrombolytic therapy to a broader population of acute stroke patients.Entities:
Mesh:
Year: 2011 PMID: 21640303 PMCID: PMC3109317 DOI: 10.1016/j.nic.2011.02.008
Source DB: PubMed Journal: Neuroimaging Clin N Am ISSN: 1052-5149 Impact factor: 2.264